Literature DB >> 20541383

Global muscle dysfunction as a risk factor of readmission to hospital due to COPD exacerbations.

Jordi Vilaró1, Alba Ramirez-Sarmiento, Juana M A Martínez-Llorens, Teresa Mendoza, Miguel Alvarez, Natalia Sánchez-Cayado, Angeles Vega, Elena Gimeno, Carlos Coronell, Joaquim Gea, Josep Roca, Mauricio Orozco-Levi.   

Abstract

UNLABELLED: Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with several modifiable (sedentary life-style, smoking, malnutrition, hypoxemia) and non-modifiable (age, co-morbidities, severity of pulmonary function, respiratory infections) risk factors. We hypothesise that most of these risk factors may have a converging and deleterious effects on both respiratory and peripheral muscle function in COPD patients.
METHODS: A multicentre study was carried out in 121 COPD patients (92% males, 63 ± 11 yr, FEV(1), 49 ± 17%pred). Assessments included anthropometrics, lung function, body composition using bioelectrical impedance analysis (BIA), and global muscle function (peripheral muscle (dominant and non-dominant hand grip strength, HGS), inspiratory (PI(max)), and expiratory (PE(max)) muscle strength). GOLD stage, clinical status (stable vs. non-stable) and both current and past hospital admissions due to COPD exacerbations were included as covariates in the analyses.
RESULTS: Respiratory and peripheral muscle weakness were observed in all subsets of patients. Muscle weakness, was significantly associated with both current and past hospitalisations. Patients with history of multiple admissions showed increased global muscle weakness after adjusting by FEV(1) (PE(max), OR = 6.8, p < 0.01; PI(max), OR = 2.9, p < 0.05; HGSd, OR = 2.4, and HGSnd, OR = 2.6, p = 0.05). Moreover, a significant increase in both respiratory and peripheral muscle weakness, after adjusting by FEV(1), was associated with current acute exacerbations.
CONCLUSIONS: Muscle dysfunction, adjusted by GOLD stage, is associated with an increased risk of hospital admissions due to acute episodes of exacerbation of the disease. Current exacerbations further deteriorate muscle dysfunction.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20541383     DOI: 10.1016/j.rmed.2010.05.001

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  33 in total

Review 1.  Molecular and biological pathways of skeletal muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  Esther Barreiro; Joaquim Gea
Journal:  Chron Respir Dis       Date:  2016-04-06       Impact factor: 2.444

2.  Muscle dysfunction in patients with lung diseases: a growing epidemic.

Authors:  Esther Barreiro; Jacob I Sznajder; Gustavo A Nader; G R Scott Budinger
Journal:  Am J Respir Crit Care Med       Date:  2015-03-15       Impact factor: 21.405

Review 3.  Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction.

Authors:  Joaquim Gea; Carme Casadevall; Sergi Pascual; Mauricio Orozco-Levi; Esther Barreiro
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

4.  Respiratory motor training and neuromuscular plasticity in patients with chronic obstructive pulmonary disease: A pilot study.

Authors:  Alexander V Ovechkin; Dimitry G Sayenko; Elena N Ovechkina; Sevda C Aslan; Teresa Pitts; Rodney J Folz
Journal:  Respir Physiol Neurobiol       Date:  2016-04-29       Impact factor: 1.931

5.  Role of Physical Therapists in Reducing Hospital Readmissions: Optimizing Outcomes for Older Adults During Care Transitions From Hospital to Community.

Authors:  Jason R Falvey; Robert E Burke; Daniel Malone; Kyle J Ridgeway; Beth M McManus; Jennifer E Stevens-Lapsley
Journal:  Phys Ther       Date:  2016-03-03

6.  Comprehensive metabolic flux analysis to explain skeletal muscle weakness in COPD.

Authors:  Mariëlle P K J Engelen; Renate Jonker; John J Thaden; Gabriella A M Ten Have; Moon Sun Jeon; Srinivasan Dasarathy; Nicolaas E P Deutz
Journal:  Clin Nutr       Date:  2020-01-29       Impact factor: 7.324

Review 7.  Muscle atrophy in chronic obstructive pulmonary disease: molecular basis and potential therapeutic targets.

Authors:  Esther Barreiro; Ariel Jaitovich
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 8.  Effects of aging and comorbidities on nutritional status and muscle dysfunction in patients with COPD.

Authors:  Bruno-Pierre Dubé; Pierantonio Laveneziana
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

9.  Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease. What We Know and Can Do for Our Patients.

Authors:  Ariel Jaitovich; Esther Barreiro
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

10.  Raw BIA variables are predictors of muscle strength in patients with chronic obstructive pulmonary disease.

Authors:  F de Blasio; M G Santaniello; F de Blasio; G Mazzarella; A Bianco; L Lionetti; F M E Franssen; L Scalfi
Journal:  Eur J Clin Nutr       Date:  2017-09-13       Impact factor: 4.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.